Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138734

Published: 2020

Journal Articles

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Jingjing Li, Xinan Lu, Jianqiang Li, PhD, Xiangqun Li, Zhongwei Xu, Ziyu Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136897

Published: 2020

Journal Articles

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Jiasheng Wang, Yue Liu, Junfang Yang, Jingjing Li, Gailing Zhang, MD, Yanze Shi, Jiujiang He, Dan Song, Wenqian Li, Shulian Xia, Min Zhang, Zhixiao Zhou, Lemei Jia, Hongli Zheng, Xin Lin, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136833

Published: 2020

Journal Articles

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Junfang Yang, Pengfei Jiang, Xian Zhang, MD, Jingjing Li, Yan Wu, Li Xu, Yunchao Su, Xiaona Hu, Xiaoyan Zhao, Qi Dong, Songbai Cai, Zhenguang Wang, Yuezhang Chen, Xun Ye, Jiaping He, Nanjing Lin, Wei Cao, Martina Sersch, MD PhD, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136866

Published: 2020

Journal Articles

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Xian Zhang, MD, Junfang Yang, Wenqian Li, Gailing Zhang, MD, Yunchao Su, Yanze Shi, Dan Song, Min Zhang, Jiujiang He, Li Xu, Liyuan Qiu, Xin-An Lu, Fei Wu, Jianqiang Li, PhD, Dandan Chen, Xiangqun Li, Ziyu Li, Jingjing Li, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-137299

Published: 2020

Journal Articles

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Jianping Zhang, Junfang Yang, Xian Zhang, MD, Jingjing Li, Xingyu Cao, Yanli Zhao, Zhijie Wei, Deyan Liu, Min Xiong, Yue Lu, Jiarui Zhou, Ruijuan Sun, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136014

Published: 2020

Journal Articles

Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia

Junfang Yang, MD, Pengfei Jiang, Xian Zhang, MD, Xiaobin Zhu, Qi Dong, Jiaping He, Nanjing Lin, Zhenguang Wang, Songbai Cai, Xun Ye, Yunchao Su, Wenqian Li, Jingjing Li, Ziyao Yu, Jiujiang He, Li Xu, Dan Song, Wei Cao, Peihua Lu

Blood (2019) 134 (Supplement_1): 284.

https://doi.org/10.1182/blood-2019-126429

Published: 2019

Journal Articles

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Xian Zhang, MD, Junfang Yang, MD, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, PhD, Fei Wu, Jianqiang Li, Ph. D., Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu

Blood (2019) 134 (Supplement_1): 224.

https://doi.org/10.1182/blood-2019-125503

Published: 2019

Journal Articles

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Jianqiang Li, PhD, Jin-Yuan Ho, PhD, Lin Wang, Xing Niu, Min Ba, Qinglong Wang, Junfang Yang, MD, Xian Zhang, MD, Dandan Chen, Peihua Lu

Blood (2019) 134 (Supplement_1): 54.

https://doi.org/10.1182/blood-2019-125467

Published: 2019

Journal Articles

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 825.

https://doi.org/10.1182/blood-2019-121751

Published: 2019

Journal Articles

Clonal Evolution of BCR-ABL1 Kinase Domain Mutation In Tyrosine Kinase Inhibitor Treatment Patient

Hongxing Liu, Ping Zhu, MD, Chunrong Tong, MD, Yanli Zhao, Peng Cai, Juan Zhu, Fang Wang, Jiangying Gu, MD, Jianjun Xie, MD, Xian Zhang, MD, Dao-Pei Lu, MD

Blood (2010) 116 (21): 597.

https://doi.org/10.1182/blood.V116.21.597.597

Published: 2010

Journal Articles

Predictable Recurrence by Regular Monitoring Minimal Residual Disease with Flowcytometry In the Patients with Both AML and ALL: A Single-Center Study of 158 Cases.

Chunrong Tong, MD, Junfang Yang, MD, Yuehui Lin, MD, Xinhong Fei, MD, Jie Zhao, MD, Xian Zhang, MD, Jiangying Gu, MD, Tong Wu, MD, Dao-Pei Lu, MD, Hui Wang, MD

Blood (2010) 116 (21): 1661.

https://doi.org/10.1182/blood.V116.21.1661.1661

Published: 2010

Journal Articles

High Frequency of Familial Hemophagocytic Lymphocytosis Associated Immune Gene Defects In Refractory Viral Infection of Unknown Origin

Chunrong Tong, MD, Hongxing Liu, Jianjun Xie, MD, Hui Wang, MD, Xian Zhang, MD, Fang Wang, Juan Zhu, Wen Teng, Jiangying Gu, MD, Yali Zhang, MD, Wenjun Ling, MD, Tong Wu, MD, Dao-Pei Lu, MD

Blood (2010) 116 (21): 2775.

https://doi.org/10.1182/blood.V116.21.2775.2775

Published: 2010

NARROW

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia

Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Clonal Evolution of BCR-ABL1 Kinase Domain Mutation In Tyrosine Kinase Inhibitor Treatment Patient

Predictable Recurrence by Regular Monitoring Minimal Residual Disease with Flowcytometry In the Patients with Both AML and ALL: A Single-Center Study of 158 Cases.

High Frequency of Familial Hemophagocytic Lymphocytosis Associated Immune Gene Defects In Refractory Viral Infection of Unknown Origin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only